Privium Fund Management B.V. Buys 2,900 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

Privium Fund Management B.V. boosted its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 45.7% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 9,250 shares of the company’s stock after acquiring an additional 2,900 shares during the period. Krystal Biotech accounts for about 0.3% of Privium Fund Management B.V.’s portfolio, making the stock its 29th biggest position. Privium Fund Management B.V.’s holdings in Krystal Biotech were worth $1,449,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in KRYS. US Bancorp DE increased its stake in Krystal Biotech by 8.7% in the fourth quarter. US Bancorp DE now owns 1,027 shares of the company’s stock valued at $161,000 after acquiring an additional 82 shares during the last quarter. Crossmark Global Holdings Inc. boosted its holdings in shares of Krystal Biotech by 5.5% in the 4th quarter. Crossmark Global Holdings Inc. now owns 2,307 shares of the company’s stock valued at $362,000 after purchasing an additional 121 shares in the last quarter. Perigon Wealth Management LLC increased its stake in shares of Krystal Biotech by 1.5% in the 4th quarter. Perigon Wealth Management LLC now owns 8,289 shares of the company’s stock valued at $1,200,000 after purchasing an additional 123 shares during the last quarter. KBC Group NV raised its holdings in shares of Krystal Biotech by 25.9% during the 3rd quarter. KBC Group NV now owns 642 shares of the company’s stock worth $117,000 after buying an additional 132 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Krystal Biotech by 3.4% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,614 shares of the company’s stock worth $840,000 after buying an additional 153 shares during the last quarter. 86.29% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts have issued reports on the company. Jefferies Financial Group began coverage on Krystal Biotech in a research report on Wednesday, March 5th. They issued a “buy” rating and a $245.00 target price on the stock. HC Wainwright reiterated a “buy” rating and set a $221.00 price objective on shares of Krystal Biotech in a research report on Friday, February 28th. Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 target price on shares of Krystal Biotech in a research report on Thursday, February 20th. Citigroup increased their price target on Krystal Biotech from $206.00 to $215.00 and gave the company a “neutral” rating in a research note on Thursday, February 20th. Finally, Chardan Capital boosted their price objective on Krystal Biotech from $212.00 to $218.00 and gave the stock a “buy” rating in a research report on Thursday, February 20th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Krystal Biotech presently has a consensus rating of “Buy” and an average price target of $220.00.

Krystal Biotech Trading Up 0.9 %

NASDAQ KRYS opened at $188.50 on Wednesday. The firm has a market capitalization of $5.43 billion, a PE ratio of 63.04 and a beta of 0.87. The business’s 50-day moving average price is $164.69 and its two-hundred day moving average price is $173.58. Krystal Biotech, Inc. has a 12 month low of $141.72 and a 12 month high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last announced its earnings results on Monday, February 24th. The company reported $1.52 EPS for the quarter, beating the consensus estimate of $1.29 by $0.23. The business had revenue of $91.10 million for the quarter, compared to analysts’ expectations of $91.35 million. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The firm’s revenue was up 116.4% on a year-over-year basis. During the same period in the prior year, the business posted $0.30 earnings per share. As a group, analysts forecast that Krystal Biotech, Inc. will post 6.14 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $177.79, for a total value of $4,444,750.00. Following the transaction, the insider now owns 1,463,711 shares in the company, valued at $260,233,178.69. The trade was a 1.68 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CAO Kathryn Romano sold 750 shares of the stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $175.22, for a total value of $131,415.00. Following the sale, the chief accounting officer now owns 12,604 shares of the company’s stock, valued at approximately $2,208,472.88. The trade was a 5.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 14.10% of the company’s stock.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).